secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001193125-23-058118
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia amends Auryxia supply agreement with Siegfried; extends term to Dec 2024 with option to 2026
--------------------------------------------------------------------------------

- Amendment No. 5 to Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.
- Akebia commits to purchase minimum quantity of Auryxia drug substance at predetermined price.
- Term extended to Dec 31, 2024; Company has option to extend to Dec 31, 2026 with 12 months notice.
- No other financial terms disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/0001193125-23-058118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523058118/d447916d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-058118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer